SM001 (alidornase/Tigerase)
Pulmonary Sarcoidosis
Key Facts
About SarcoMed USA
SarcoMed USA is a private, preclinical-stage biotech company targeting significant unmet needs in pulmonary inflammation, primarily pulmonary sarcoidosis. Its core strategy involves repurposing or licensing inhaled DNase 1 enzyme therapy (SM001) to break down pro-inflammatory extracellular DNA complexes implicated in granuloma formation. The company has completed a Pre-IND meeting with the FDA, secured orphan designation, and is exploring additional indications like ARDS and IPF, while also holding an option on an immuno-oncology asset. It appears to be pre-revenue and is advancing toward clinical trials.
View full company profileAbout SarcoMed USA
SarcoMed USA is a private, preclinical-stage biotech company targeting significant unmet needs in pulmonary inflammation, primarily pulmonary sarcoidosis. Its core strategy involves repurposing or licensing inhaled DNase 1 enzyme therapy (SM001) to break down pro-inflammatory extracellular DNA complexes implicated in granuloma formation. The company has completed a Pre-IND meeting with the FDA, secured orphan designation, and is exploring additional indications like ARDS and IPF, while also holding an option on an immuno-oncology asset. It appears to be pre-revenue and is advancing toward clinical trials.
View full company profileAbout SarcoMed USA
SarcoMed USA is a private, preclinical-stage biotech company targeting significant unmet needs in pulmonary inflammation, primarily pulmonary sarcoidosis. Its core strategy involves repurposing or licensing inhaled DNase 1 enzyme therapy (SM001) to break down pro-inflammatory extracellular DNA complexes implicated in granuloma formation. The company has completed a Pre-IND meeting with the FDA, secured orphan designation, and is exploring additional indications like ARDS and IPF, while also holding an option on an immuno-oncology asset. It appears to be pre-revenue and is advancing toward clinical trials.
View full company profileAbout SarcoMed USA
SarcoMed USA is a private, preclinical-stage biotech company targeting significant unmet needs in pulmonary inflammation, primarily pulmonary sarcoidosis. Its core strategy involves repurposing or licensing inhaled DNase 1 enzyme therapy (SM001) to break down pro-inflammatory extracellular DNA complexes implicated in granuloma formation. The company has completed a Pre-IND meeting with the FDA, secured orphan designation, and is exploring additional indications like ARDS and IPF, while also holding an option on an immuno-oncology asset. It appears to be pre-revenue and is advancing toward clinical trials.
View full company profileTherapeutic Areas
Other Pulmonary Sarcoidosis Drugs
| Drug | Company | Phase |
|---|---|---|
| XTMAB-16 | Xentria | Phase 2 |
| Efzofitimod (ATYR1923) | aTyr Pharma | Phase 3 |